BACKGROUND & AIMS: Esophageal adenocarcinoma is believed to result from the progression of gastroesophageal reflux disease to erosive esophagitis and re-epithelialization of the esophagus with a columnar cell population termed Barrett's esophagus (BE). Men develop BE and esophageal adenocarcinoma more frequently than women, yet little is known about the mechanisms of this difference. We assessed whether sex steroid hormones were associated with BE in a male population. METHODS: We analyzed data from the Barrett's Esophagus Early Detection Case Control Study, based at the Walter Reed National Military Medical Center. Blood samples were collected from 174 men with BE and 213 men without BE (controls, based on endoscopic analysis); 13 sex steroid hormones were measured by mass spectrometry and sex hormone binding globulin was measured by enzyme-linked immunosorbent assay. We also calculated free estradiol, free testosterone, and free dihydrotestosterone (DHT). We used multivariable logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs) adjusted for age, race, smoking status, alcohol consumption, body mass index, heartburn, regurgitation, and gastroesophageal symptom score (excluding heartburn and regurgitation). RESULTS: Levels of free testosterone and free DHT were associated positively with BE risk; patients in the highest quartile for these hormones were most likely to have BE (free testosterone: OR, 5.36; 95% CI, 2.21-13.03; P = .0002; free DHT: OR, 4.25; 95% CI, 1.87-9.66; P = .001). Level of estrone sulfate was associated inversely with BE risk (P for trend = .02). No other hormone was associated with BE risk. Relationships were not modified by age or BMI. CONCLUSIONS: In an analysis of men, levels of free testosterone and free DHT were significantly associated with BE.
BACKGROUND & AIMS:Esophageal adenocarcinoma is believed to result from the progression of gastroesophageal reflux disease to erosive esophagitis and re-epithelialization of the esophagus with a columnar cell population termed Barrett's esophagus (BE). Men develop BE and esophageal adenocarcinoma more frequently than women, yet little is known about the mechanisms of this difference. We assessed whether sex steroid hormones were associated with BE in a male population. METHODS: We analyzed data from the Barrett's Esophagus Early Detection Case Control Study, based at the Walter Reed National Military Medical Center. Blood samples were collected from 174 men with BE and 213 men without BE (controls, based on endoscopic analysis); 13 sex steroid hormones were measured by mass spectrometry and sex hormone binding globulin was measured by enzyme-linked immunosorbent assay. We also calculated free estradiol, free testosterone, and free dihydrotestosterone (DHT). We used multivariable logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs) adjusted for age, race, smoking status, alcohol consumption, body mass index, heartburn, regurgitation, and gastroesophageal symptom score (excluding heartburn and regurgitation). RESULTS: Levels of free testosterone and free DHT were associated positively with BE risk; patients in the highest quartile for these hormones were most likely to have BE (free testosterone: OR, 5.36; 95% CI, 2.21-13.03; P = .0002; free DHT: OR, 4.25; 95% CI, 1.87-9.66; P = .001). Level of estrone sulfate was associated inversely with BE risk (P for trend = .02). No other hormone was associated with BE risk. Relationships were not modified by age or BMI. CONCLUSIONS: In an analysis of men, levels of free testosterone and free DHT were significantly associated with BE.
Authors: David Furman; Boris P Hejblum; Noah Simon; Vladimir Jojic; Cornelia L Dekker; Rodolphe Thiébaut; Robert J Tibshirani; Mark M Davis Journal: Proc Natl Acad Sci U S A Date: 2013-12-23 Impact factor: 11.205
Authors: Suman Kambhampati; Roger A Rajewski; Mehmet Tanol; Inamul Haque; Amlan Das; Snigdha Banerjee; Saheli Jha; Douglas Burns; Emma Borrego-Diaz; Peter J Van Veldhuizen; Sushanta K Banerjee Journal: Mol Cancer Ther Date: 2013-01-03 Impact factor: 6.261
Authors: Cathrine Hoyo; Michael B Cook; Farin Kamangar; Neal D Freedman; David C Whiteman; Leslie Bernstein; Linda M Brown; Harvey A Risch; Weimin Ye; Linda Sharp; Anna H Wu; Mary H Ward; Alan G Casson; Liam J Murray; Douglas A Corley; Olof Nyrén; Nirmala Pandeya; Thomas L Vaughan; Wong-Ho Chow; Marilie D Gammon Journal: Int J Epidemiol Date: 2012-11-12 Impact factor: 7.196
Authors: Ai Kubo; Michael Blaise Cook; Nicholas J Shaheen; Thomas L Vaughan; David C Whiteman; Liam Murray; Douglas A Corley Journal: Gut Date: 2013-01-26 Impact factor: 23.059
Authors: M B Cook; S Wood; P L Hyland; P Caron; J Drahos; R T Falk; R M Pfeiffer; S M Dawsey; C C Abnet; P R Taylor; C Guillemette; L J Murray; L A Anderson Journal: Andrology Date: 2017-02-27 Impact factor: 3.842
Authors: Jessica L Petrick; Paula L Hyland; Patrick Caron; Roni T Falk; Ruth M Pfeiffer; Sanford M Dawsey; Christian C Abnet; Philip R Taylor; Stephanie J Weinstein; Demetrius Albanes; Neal D Freedman; Susan M Gapstur; Gary Bradwin; Chantal Guillemette; Peter T Campbell; Michael B Cook Journal: J Natl Cancer Inst Date: 2019-01-01 Impact factor: 13.506
Authors: Melina Arnold; Amy Colquhoun; Michael B Cook; Jacques Ferlay; David Forman; Isabelle Soerjomataram Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-10-22 Impact factor: 4.254
Authors: Shao-Hua Xie; Rui Fang; Mingtao Huang; Juncheng Dai; Aaron P Thrift; Lesley A Anderson; Wong-Ho Chow; Leslie Bernstein; Marilie D Gammon; Harvey A Risch; Nicholas J Shaheen; Brian J Reid; Anna H Wu; Prasad G Iyer; Geoffrey Liu; Douglas A Corley; David C Whiteman; Carlos Caldas; Paul D Pharoah; Laura J Hardie; Rebecca C Fitzgerald; Hongbing Shen; Thomas L Vaughan; Jesper Lagergren Journal: Clin Gastroenterol Hepatol Date: 2019-11-19 Impact factor: 11.382
Authors: Úna C Mc Menamin; Andrew T Kunzmann; Michael B Cook; Brian T Johnston; Liam J Murray; Andrew D Spence; Marie M Cantwell; Chris R Cardwell Journal: Int J Cancer Date: 2018-03-30 Impact factor: 7.396